Cancer history: A predictor of IPMN subtype and dysplastic status?

Rosalie A Carr,Brandon A Kiel,Alexandra M Roch,Eugene P Ceppa,Michael G House,Nicholas J Zyromski,Attila Nakeeb,C Max Schmidt

doi:10.1016/j.amjsurg.2017.11.014

Rosalie A Carr, Brandon A Kiel + Show 6 more

Open Access

https://doi.org/10.1016/j.amjsurg.2017.11.014

Copy DOI

Abstract

IntroductionThe aim of this study was to determine the association of PMH and FH of pancreatic (PDAC) and non-pancreatic cancers with IPMN malignant risk. MethodsA retrospective review of a prospective database of IPMN patients undergoing resection was performed to assess FH and PMH. ResultsFH of PDAC was present in 13% of 362 included patients. Of these, 8% had at least one first degree relative (FDR) with PDAC. The rate of PDAC positive FH in non-invasive versus invasive IPMN patients was 14% and 8%, respectively (p = 0.3). In main duct IPMN patients, FH (44%) and PMH of non-pancreatic cancer (16%) was higher than that seen in branch duct IPMN (FH 29%; PMH 6%; p = 0.004 and 0.008). ConclusionsFH of PDAC is not associated with IPMN malignant progression. FH and PMH of non-pancreatic cancer is associated with main duct IPMN, the subtype with the highest rate of invasive transformation.

Full Text